Airworthiness Safety Conference 2025: In-depth Discussions, Idea Sharing, and Significant Networking Opportunities (London, United Kingdom - October 21, 2025)
The 'Safety in Airworthiness' conference has been added to ResearchAndMarkets.com's offering.
Renowned speakers will participate in this new global event in London.
The conference sessions act as an engaging forum, promoting in-depth discussions, idea sharing, and significant networking opportunities.
Agenda Highlights:
Agenda:
8.45 - Registration & Networking Coffee
9.15 - Opening Remarks
Panagiotis Panagopoulos, CEO & Founder, Aeropodium
Ian Dearing, Chief Surveyor - Airworthiness, 2-REG Aircraft Registry
9.45 - Introduction - A Regulator's View of Safety in Airworthiness
Ian Dearing, Chief Surveyor - Airworthiness, 2-REG Aircraft Registry
10.15 - Safety in Part 21 - What is the Industry Seeing?
Jack Coleman, Initial Airworthiness, Independent Consultant
10.45 - Measuring Safety in Continuing Airworthiness
Paul White, Continuing Airworthiness, Independent Consultant
11.15 - Networking Coffee Break
11.45 - Delivering the Next Generation of Safety Professionals
Nicola Osborne, Director Safety & Compliance, Titan Airways
12.15 - Influencing Aviation Safety Behaviours and Promoting Wellbeing
Sam Lee, Managing Director, Integra Aerospace
12.45 - Networking Lunch Break
13.45 - Worldwide Safety Management Systems Issues, and How to Solve Them
Silas Hays, Safety Management, Independent Consultant
14.30 - Remote Pilot Air Systems - Beyond Visual Line of Sight Operations
Becky Smith, Continuing Airworthiness Manager, National Grid
15.00 - Networking Coffee Break
15.30 - Speakers' Panel Q&A
16.30 - Concluding Remarks
Speakers
For more information about this conference visit https://www.researchandmarkets.com/r/333xc0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250605768918/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: TRANSPORT AIR
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 06/05/2025 07:10 AM/DISC: 06/05/2025 07:09 AM
http://www.businesswire.com/news/home/20250605768918/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Pear Protocol Goes Live with Hyperliquid Integration and Announces $4.1M Strategic Round Led by Castle Island Ventures
London, UK, July 28th, 2025, ChainwirePear Protocol, the premier pair trading platform in crypto, has officially launched its native integration with Hyperliquid, unlocking seamless pair trading on top of the Hyperliquid perpetual orderbook. This launch coincides with the closing of a $4.1M strategic funding round led by Castle Island Ventures, with participation from Compound VC, Florin Digital and Sigil Fund. The raise comes as Pear Protocol nears $1BN in trading volume, powering over 4,000 traders with daily volumes in beta already above $5M+. 'Hyperliquid is where the best traders are, and Pear now provides the best way to pair trade on top of that liquidity,' said Huf, Founder of Pear Protocol. 'This round marks a turning point - our investors deeply understand the space, and together we're going full throttle on execution.' What This Means for Users With the Hyperliquid integration now live, traders on Pear can enjoy: Continued eligibility for any Hyperliquid Season 3 points and HyPear Points, converting into claimable $HYPE One-click entry and exit across both legs of a pair trade Limit and TWAP execution on the ratio, optimising entry and exits TP/SL logic based on the ratio for superior risk management Direct ratio charting, net funding differentials, and custom pair weighting tools Pear makes advanced strategies simple, mobile-friendly, and capital-efficient - whether you're trading HYPE/SOL or building custom ETH/BTC trades with beta-weighted logic. Strategic Use of Funds The new capital will be deployed to: Expand Pear's institutional-grade product suite Launch vaults and APIs on HyperEVM Re-launch their spot token with deeper liquidity on Hyperliquid's Spot Orderbook Accelerate user growth and talent acquisition Position Pear for long-term sustainability – including optional protocol buybacks and new revenue lines This round strategically aligns Pear Protocol with some of the most respected players in crypto venture, each bringing ecosystem reach, product insight, and long-term conviction. 'We believe Pear is building trading infrastructure for the next wave of DeFi-native professionals,' said Wyatt Khosrowshahi, Investor at Castle Island Ventures. 'They're connecting deep crypto-native liquidity with intuitive UX, timely education, and novel execution.' About Pear Protocol Pear Protocol is the leading DeFi-native pair trading terminal, enabling users to trade one token against another with high capital efficiency. With integrations across major venues including Hyperliquid, GMX and SYMMIO, Pear serves both professional retail and institutional users. Learn more at Users can follow Pear Protocol's Twitter (@pear_protocol) account for more Protocolhuf@ pear_protocol Permalink | © Copyright 2025 All rights reserved
Yahoo
9 minutes ago
- Yahoo
Tesla, Samsung, energy stocks, & European semiconductors climb
Yahoo Finance's John Hyland outlines some of the top stories on Wall Street as part of Yahoo Finance's Market Minute. Energy stocks, like Cheniere Energy (LNG) and Venture Global (VG), are moving higher on the back of the US–EU trade deal. Tesla (TSLA) stock is climbing after CEO Elon Musk announced that the company signed a $16.5 billion chip deal with Samsung ( European semiconductor companies, like ASML Holding (ASML) and STMicroelectronics (STM), are moving to the upside from both the US–EU trade deal and the Tesla–Samsung chip deal. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo! Finance's market minute. US stocks are trading at record highs today after the US and the EU struck a trade deal over the weekend that will see a 15% tariff imposed on goods from the European Union. US energy stocks moving higher on the back of the deal. As Trump said that the EU agreed to purchase $750 billion in American energy products and invest $600 billion in the US on top of existing commitments. EU president Ursula von der Leyen said the purchases would help reduce the bloc's dependence on Russia for natural gas. Plus, Tesla striking a $16.5 billion deal with Samsung to produce AI chips for the EV maker. CEO Elon Musk confirmed the news on X, saying Samsung's giant new Texas fab will be dedicated to making Tesla's next generation AI6 chip. And shares of European semiconductor companies getting a boost off the back of the Samsung deal and the EU US trade deal. The agreement exempts tariffs on semiconductor equipment, giving an additional boost to the sector after its two-week long slide. And that's your Yahoo! Finance market minute.
Yahoo
9 minutes ago
- Yahoo
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
By Bhanvi Satija (Reuters) -The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation, but others cautioned that the deal was not yet signed and that several questions remained unanswered. UBS analyst Matthew Weston said that he expects details of the trade deal to include protective measures for EU pharma exports from the U.S. investigation, especially since such measures are being discussed in negotiations with the United Kingdom and Switzerland. ING analyst Diederik Stadig also said that while tariffs on top of the 15% were not expected, even after the conclusion of the national security investigations, nothing is completely clear "until a trade deal is inked." Stadig estimates that these levies could add $13 billion to industry expenses without any mitigation strategies, and some of that could be ultimately borne by the consumer. Bernstein analyst Courtney Breen puts the additional expenses at $19 billion for the industry, but she notes that companies might be able to absorb some of the costs with the measures they have been implementing — such as stockpiling of drug products and new deals with contract researchers. Earlier this month, Sanofi said it will sell a manufacturing facility in New Jersey to Thermo Fisher, where the French drugmaker's therapies will continue to be manufactured. Roche's CEO Thomas Schinecker said last week that the company was increasing its U.S. inventories to avoid any immediate disruption from tariffs. UBS' Weston said that it was not immediately clear which generic drugs were exempted from duties under the deal, but any impact for generic drugmaker Sandoz for this year should mostly be manageable. Shares in pharmaceutical companies Sanofi, Roche and Sandoz Group all closed up between 0.5% and 1% on Monday.
